New trial
Phase 2 GdContrast: Gadolinium agent enhances T1 relaxation for improved margin visualization
- Trial ID
- NCT07060261 on ClinicalTrials.gov
- Cancer type
- Tonsillar Cancer
- Stage of research
- Exploratory
- Published in
- New in Oncology - July 25, 2025
This prospective study sponsored by Case Comprehensive Cancer Center evaluates whether enhanced pre-operative MRI protocols—including noncontrast, contrast-enhanced, T2 weighted, and T2 SPACE sequences—can predict margin status during transoral robotic surgery in patients with HPV+ tonsillar squamous cell carcinoma. Three neuroradiologists independently grade pharyngeal muscle thickness, aiming to inform surgical planning and optimize patient outcomes.
More in head and neck cancer
-
Trial result · Oct 15, 2026 · NCT05323656
Setanaxib + pembrolizumab misses its tumor-shrinkage endpoint but shows exploratory survival signals in CAF-rich head and neck cancer -
Trial result · Oct 1, 2026 · NCT04260126
PDS0101 (HPV16-targeted immunotherapy) + pembrolizumab drives 34% ORR and 39.3-mo mOS in 1L HPV16+ R/M HNSCC -
New trial · Sep 24, 2026 · NCT07773987
Phase 2 pembrolizumab PD-1 inhibitor plus hypofractionated RT tests ENI nodal-sparing strategy -
New trial · Sep 24, 2026 · NCT07807163
Phase 2 ficerafusp alfa (BCA101) EGFR×TGF-β bifunctional antibody + pembrolizumab -
New trial · Sep 24, 2026 · NCT07796126
Phase 2 toripalimab PD-1 (CD279) antibody “priming” before paclitaxel microtubule inhibitor in HNSCC
